Preparing for a Health Canada GMP Inspection — A Practical Readiness Checklist

A pharmaceutical manufacturer receives notification that Health Canada will conduct a GMP inspection of their facility in six weeks. The quality director’s first instinct is to schedule a document review. But document review alone is not inspection preparation. Health Canada inspectors assess not just whether documents exist, but whether the quality system described in those documents is actually functioning as written — and whether the people responsible for running it understand it.

This article is for quality and regulatory teams at pharmaceutical manufacturers, CMOs, and CROs preparing for a Health Canada GMP inspection. We outline the key areas inspectors focus on, the preparation activities that make the most difference, and how to respond effectively when observations are issued.

Understanding Health Canada’s Inspection Approach

Health Canada conducts GMP inspections of drug establishments under the authority of the Food and Drugs Act and the Food and Drug Regulations. Inspections are conducted by inspectors from the Health Products and Food Branch (HPFB) Inspectorate. The inspection program is risk-based — the frequency and depth of inspection depend on the establishment’s compliance history, the risk profile of the activities performed, and the drug classes involved.

Inspections may be:

• Routine: Scheduled inspections conducted as part of the regular inspection cycle
• For-cause: Triggered by a specific compliance concern, complaint, or adverse event
• Pre-licence: Conducted before a Drug Establishment Licence is issued or amended
• Follow-up: Conducted to verify that corrective actions from a previous inspection have been implemented

For most established manufacturers, routine inspections are the most common type. The notification period for routine inspections varies and may be short. Facilities should maintain a state of inspection readiness at all times rather than treating inspection preparation as a periodic event.

Key Areas Health Canada Inspectors Focus On

Based on publicly available Health Canada inspection guidance and our experience supporting facilities through the inspection process, the following areas receive consistent attention:

1. Data Integrity

Data integrity is one of the most significant areas of focus in current GMP inspections globally, and Health Canada is no exception. Inspectors assess whether:

• Audit trails are enabled on all computerized systems (chromatography data systems, balances, environmental monitoring systems)
• Audit trails are reviewed as part of routine data review and not just during investigations
• Individual login credentials are used (shared credentials are a data integrity vulnerability)
• Raw data is retained and accessible — including original instrument output, not just processed results
• There is a procedure for handling data integrity incidents, and it has been used appropriately

Data integrity findings are among the most serious that Health Canada can issue, because they call into question the reliability of all data generated at the facility. Preparation in this area should include a thorough review of all computerized systems and their audit trail configurations.

2. Out-of-Specification (OOS) Investigations

Health Canada inspectors review OOS investigation records closely. They assess whether:

• The OOS investigation procedure is documented and followed consistently
• Phase 1 (laboratory investigation) is completed before Phase 2 (full investigation) is initiated
• OOS results are not invalidated without documented evidence of an assignable laboratory error
• Retesting is conducted only within the framework of the investigation procedure, not as a substitute for investigation
• Conclusions are scientifically defensible and documented

A common finding is the invalidation of OOS results based on insufficient evidence — for example, invalidating a result because a retest passes, without identifying the specific laboratory error that caused the original OOS. Inspectors will review the complete OOS file, including the original data, the investigation narrative, and the conclusion.

3. Change Control

Change control is a systemic area — inspectors assess not just individual change records but whether the change control system is functioning as intended. They look for:

• Changes that were implemented without going through change control
• Changes that were classified at an inappropriate risk level (e.g., a significant change treated as minor)
• Changes that required revalidation but where revalidation was not performed
• Changes to computerized systems that were not captured in the change control system

Preparation should include a review of recent changes to identify any that may have been implemented outside the change control system or that may require additional documentation.

4. Validation Status

Inspectors assess whether critical processes, cleaning procedures, and analytical methods are validated and whether the validation status is current. Key questions include:

• Are all commercial manufacturing processes validated (or covered by a process performance qualification program)?
• Are cleaning procedures validated for all shared equipment?
• Are analytical methods validated per ICH Q2(R1)?
• Has revalidation been triggered by any changes, and has it been completed?

Validation master plans and validation status summaries are useful tools for demonstrating the overall validation status of the facility to an inspector.

5. Training

Inspectors assess whether personnel are trained on the procedures relevant to their roles and whether training records are current. They may ask personnel directly about procedures — a person who cannot describe the procedure they are supposed to follow, or who describes a practice that differs from the written procedure, is a finding.

Preparation should include a review of training records for completeness and a check that procedures have been updated to reflect current practice (not the reverse — updating practice to match outdated procedures is not sufficient).

6. Supplier Qualification

Inspectors assess whether suppliers of critical materials — including APIs, excipients, and primary packaging — have been qualified and whether the qualification is current. For contract laboratories, inspectors may ask to see audit records and quality agreements.

Pre-Inspection Preparation Activities

The following activities are most effective in the weeks before an inspection:

Mock inspection: Conduct an internal mock inspection using the same areas of focus as a Health Canada inspection. Use personnel who were not involved in preparing the documents being reviewed. Document findings and implement corrective actions before the actual inspection.

Document review: Confirm that all SOPs are current, approved, and reflect actual practice. Review recent batch records, OOS investigations, change control records, and deviation reports for completeness and consistency.

System walk-through: Walk through the facility with the inspection team to identify any visible compliance issues — labelling, cleanliness, equipment status, environmental monitoring records.

Personnel briefing: Brief all personnel who may interact with inspectors on their roles during the inspection, the importance of answering questions accurately and within their knowledge, and the procedure for escalating questions they cannot answer.

Document control check: Confirm that all documents are version-controlled, that obsolete versions have been removed from use, and that the document management system is functioning correctly.

Responding to Inspection Observations

At the conclusion of the inspection, Health Canada inspectors will communicate their observations. Observations are classified by severity, and the facility is required to respond within a specified timeframe.

Effective responses:

• Acknowledge the observation without being defensive
• Provide a root cause analysis that identifies the underlying cause, not just the immediate cause
• Describe corrective actions that address the root cause
• Provide a realistic timeline for implementation
• Commit to verifying the effectiveness of corrective actions

Responses that simply describe what was done to fix the immediate issue, without addressing the root cause, are likely to be found insufficient. Inspectors expect that the facility has understood why the issue occurred and has taken steps to prevent recurrence.

Practical Checklist: GMP Inspection Readiness

Data Integrity

• Audit trails enabled on all computerized systems
• Audit trail review included in routine data review procedures
• Individual login credentials in use; no shared credentials
• Raw data retained and accessible

OOS Investigations

• Written OOS investigation procedure in place with two-phase structure
• Recent OOS files reviewed for completeness and scientific defensibility
• No OOS results invalidated without documented assignable cause

Change Control

• Recent changes reviewed to confirm all went through change control
• Change risk classifications reviewed for appropriateness
• Revalidation requirements assessed and completed where triggered

Validation

• Validation master plan current; validation status summary available
• Cleaning validation in place for all shared equipment
• Analytical methods validated per ICH Q2(R1)

Training

• Training records current for all personnel
• Personnel can describe procedures relevant to their roles

Supplier Qualification

• Supplier qualification records current for all critical material suppliers
• Contract laboratory audit records and quality agreements available

General

• Mock inspection completed; findings addressed
• Facility walk-through completed; visible issues resolved
• Personnel briefed on inspection roles and procedures

Health Canada GMP inspections are a normal part of operating a licensed drug establishment. Requirements may vary depending on the establishment type, the drug classes involved, and the inspection type. We recommend maintaining a state of continuous inspection readiness rather than treating preparation as a periodic exercise.

At Androxa, we support pharmaceutical manufacturers and CMOs with inspection readiness assessments, mock inspections, and quality system gap analyses. Contact our team at testing-lab.ca to discuss your inspection preparation needs.